Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.
The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration, and it will stop sales of the drug.
Patients taking doses of Aduhelm available through the commercial market can continue until November. A company representative said there are about 2,500 people worldwide taking Aduhelm.
Biogen said it will turn its focus more to other Alzheimer’s treatments. It also is helping Japanese drugmaker Eisai sell another Alzheimer’s treatment, Leqembi, which already has full FDA approval.
Aduhelm was the first new Alzheimer’s disease drug introduced in nearly two decades when it received accelerated approval from the FDA in 2021. Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster drug that would generate billions for Biogen.
But doctors were hesitant to prescribe it given weak evidence that the drug slows the progression of Alzheimer’s, a fatal, mind-robbing disease. Insurers have blocked or restricted coverage, and the federal government’s Medicare program imposed strict limits on who could get it.
The drug wound up generating millions, not billions, in quarterly sales for Biogen, and the company announced in 2022 that it would largely shut down marketing of Aduhelm.
2024-12-24 06:471966 view
2024-12-24 06:231997 view
2024-12-24 06:121022 view
2024-12-24 05:312858 view
2024-12-24 05:301734 view
2024-12-24 04:521747 view
Two months after suing President-elect Donald Trump and his campaign for the unauthorized use of the
LAWRENCE, Kan. (AP) — A relative of a slain Black 14-year-old is calling for a white Kansas teen to
LAWRENCEVILLE, Ga. (AP) — Officials in Georgia’s second-largest county could ask voters in 2024 to a